Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The Anti-Biofilm Efficacy of Caffeic Acid Phenethyl Ester (CAPE) In Vitro and a Murine Model of Oral Candidiasis

Full text
Author(s):
de Barros, Patricia Pimentel [1, 2] ; Rossoni, Rodnei Dennis [1] ; Garcia, Maira Terra [1] ; Kaminski, Valeria de Lima [3] ; Loures, Flavio Vieira [3] ; Fuchs, Beth Burgwyn [4] ; Mylonakis, Eleftherios [4] ; Junqueira, Juliana Campos [1]
Total Authors: 8
Affiliation:
[1] Sao Paulo State Univ Unesp, Inst Sci & Technol, Dept Biosci & Oral Diag, Sao Jose Dos Campos - Brazil
[2] Fed Univ Rio Grande do Norte UFRN, Multicampi Sch Med Sci, Caico - Brazil
[3] Fed Univ Sao Paulo UNIFESP, Inst Sci & Technol, Appl Immunol Lab, Sao Jose Dos Campos - Brazil
[4] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Infect Dis, Providence, RI 02903 - USA
Total Affiliations: 4
Document type: Journal article
Source: FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY; v. 11, AUG 2 2021.
Web of Science Citations: 2
Abstract

Candida albicans is the main fungal species associated with the development of oral candidiasis. Currently, therapeutic options for these infections are limited by the adverse effects of antifungal drugs and by the emergence of drug resistant strains. Thus, the development of new antifungal agents is needed for the prevention and treatment of oral Candida infections. Caffeic acid phenethyl ester (CAPE) is a natural compound from propolis polyphenolic groups that exhibits many pharmacological properties. In this study, we investigated whether CAPE can have antifungal and immunomodulatory effects on oral candidiasis. Preliminary tests to assess the antifungal activity of CAPE were performed using the Minimum Inhibitory Concentration (MIC) assay that demonstrated inhibition in a range from 16 to 32 mu g/mL, confirming its antifungal activity on several C. albicans strains isolated from the oral cavity. Subsequently, we analyzed Candida spp biofilms formed in vitro, in which CAPE treatment at 5 x MIC caused a reduction of 68.5% in the total biomass and similar to 2.60 Log in the viable cell count (CFU/mL) in relation to the untreated biofilm (p < 0.0001). Next, RNA was extracted from untreated and CAPE-treated biofilms and analyzed by real-time qPCR. A series of genes analyzed (ALS1, ECE1, EPA1, HWP1, YWP1, BCR1, BGR1, CPH1, EFG1, NDT80, ROB1, TEC1, UME6, SAP2, SAP5, PBL2, and LIP9) were downregulated by CAPE compared to the untreated control group (p < 0.0001). In in vivo studies using Galleria mellonella, the treatment with CAPE prolonged survival of larvae infected by C. albicans by 44.5% (p < 0.05) and accompanied by a 2.07-fold increase in the number of hemocytes. Flow cytometry revealed the most prominent increases were in types P2 and P3 hemocytes, granular cells, which phagocytize pathogens. In addition, CAPE treatment decreased the fungal load in the hemolymph and stimulated the expression of antifungal peptide genes such as galiomicin and gallerimycin. The antifungal and immunomodulatory activities observed in G. mellonella were extended to a murine model of oral candidiasis, in which CAPE decreased the levels of C. albicans colonization (similar to 2 log CFU/mL) in relation to the untreated control group. In addition, CAPE treatment significantly reduced pseudomembranous lesions, invasion of hyphae on epithelium surfaces, tissue damage and inflammatory infiltrate (p < 0.05). CAPE was also able to increase the expression of beta-defensin 3 compared to the infected and untreated group by 3.91-fold (p < 0.0001). Taken together, these results show that CAPE has both antifungal and immunomodulatory effects, making it a promising natural antifungal agent for the treatment and prevention of candidiasis and shows impact to oral candidiasis. (AU)

FAPESP's process: 19/10097-8 - Multi-User Equipment approved in grant 2018/14762-3: flow cytometer FACS lyric
Grantee:Flávio Vieira Loures
Support Opportunities: Multi-user Equipment Program
FAPESP's process: 17/02652-6 - Evaluation of the immunomodulatory and antifungal effects of caffeic acid (CA), caffeic acid phenethyl ester (CAPE) and artepillin C (ARC) on C. albicans and development of candidiasis in in vivo model hosts
Grantee:Patrícia Pimentel de Barros
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 19/05664-0 - Exploring the caffeic acid (CA), caffeic acid phenethyl ester (CAPE) and artepillin c (ARTC) as new strategies to eliminate persisters cells of Candida albicans
Grantee:Patrícia Pimentel de Barros
Support Opportunities: Scholarships abroad - Research Internship - Post-doctor